Cargando…

886. Pregnancy Outcomes Following Raltegravir Exposure

BACKGROUND: Safety data are needed regarding HIV treatment in women of reproductive potential and during pregnancy. This review is to evaluate pregnancy outcomes following prospective exposures (exposure report prior to knowledge of pregnancy outcome) to raltegravir during pregnancy. METHODS: Exposu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shamsuddin, Hala, Raudenbush, Casey, Sciba, Brittany, Gooch, Erica N, Greaves, Wayne, Leong, Ronald W, Straus, Walter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809206/ http://dx.doi.org/10.1093/ofid/ofz359.045

Ejemplares similares

Evaluation of Neural Tube Defects (NTDs) After Exposure to Raltegravir During Pregnancy
por: Shamsuddin, Hala, et al.
Publicado: (2019)

A Health Literate Patient-focused Approach to the Redesign of the Raltegravir (ISENTRESS) Pediatric Kit and Instructions for Use
por: Mills, Alexander, et al.
Publicado: (2021)

886. Impact of Race on the Early Diagnosis and Treatment of Lyme Disease
por: Starke, Samuel J, et al.
Publicado: (2023)

Synthesis and reactivity of precolibactin 886
por: Healy, Alan R., et al.
Publicado: (2019)

886. The Impact of the COVID-19 Pandemic on Clinical Follow-Up, Monitoring and Regimen Discontinuation for People Living with HIV in the US
por: Pierone, Gerald, et al.
Publicado: (2021)

886. Impact of Type of Surgical Management on the Incidence of Recurrent Surgical Site Infections Following Hip and Knee replacements in Calgary, Alberta
por: Chavda, Swati, et al.
Publicado: (2020)

Human noncoding RNA 886 (nc886) adopts two structurally distinct conformers that are functionally opposing regulators of PKR
por: Calderon, Brenda M., et al.
Publicado: (2017)

Methylation status of nc886 epiallele reflects periconceptional conditions and is associated with glucose metabolism through nc886 RNAs
por: Marttila, Saara, et al.
Publicado: (2021)

555. Characteristics of HIV+ Patients Prescribed Raltegravir QD in the United States
por: Lackey, Philip, et al.
Publicado: (2018)

Raltegravir monohydrate
por: Yamuna, Thammarse S., et al.
Publicado: (2013)

936 Tolerability, Adherence and Completion of New Occupational HIV Post-Exposure Prophylaxis Regimens (Tenofovir + Emtricitabine and Raltegravir)
por: Bock, Izona, et al.
Publicado: (2014)

2487. Low Rate of Virologic Failure in Antiretroviral Experienced Patients Prescribed Once Daily Raltegravir
por: Hsu, Ricky, et al.
Publicado: (2019)

HIV resistance to raltegravir
por: Clavel, François
Publicado: (2009)

Treatment with Raltegravir, a retroviral integrase inhibitor, in patients infected with HTLV-1
por: Treviño, Ana, et al.
Publicado: (2011)

702. Hepatic Safety Among Patients Treated with Anti-Fungal Triazole Agent Posaconazole: Characterization of Adverse events in a Manufacturer’s Safety Database
por: Zhou, Yun-Ping, et al.
Publicado: (2019)

High levels of polymorphisms related to raltegravir resistance among raltegravir-naïve individuals in Brazil
por: Pena, N Mantovani, et al.
Publicado: (2010)

886 Correlation Between Methods to Calculate Denominators for Dialysis Event Surveillance Using Electronic Health Record Data, Tennessee, 2012
por: Nguyen, Duc, et al.
Publicado: (2014)

Methylation pattern of polymorphically imprinted nc886 is not conserved across mammalia
por: Kostiniuk, Daria, et al.
Publicado: (2022)

Drug-drug interactions with raltegravir
por: Burger, David M
Publicado: (2009)

Raltegravir in treatment naïve patients
por: Cossarini, F, et al.
Publicado: (2009)

Raltegravir use in special populations
por: Johnson, Margaret
Publicado: (2009)

Adverse events of raltegravir and dolutegravir
por: Elzi, Luigia, et al.
Publicado: (2017)

Oocyte age and preconceptual alcohol use are highly correlated with epigenetic imprinting of a noncoding RNA (nc886)
por: Carpenter, Brittany L., et al.
Publicado: (2021)

Modelling HIV-1 2-LTR dynamics following raltegravir intensification
por: Luo, Rutao, et al.
Publicado: (2013)

Are We Studying Non-Coding RNAs Correctly? Lessons from nc886
por: Lee, Yong Sun
Publicado: (2022)

Raltegravir in the management of HIV-infected patients
por: Stellbrink, Hans-Jürgen
Publicado: (2009)

Spectrophotometric Estimation of Raltegravir Potassium in Tablets
por: Kore, P. P., et al.
Publicado: (2014)

1575 A 28-day high-dose safety and pharmacokinetics study of raltegravir in healthy subjects
por: Krishna, Rajesh, et al.
Publicado: (2014)

nc886 is induced by TGF-β and suppresses the microRNA pathway in ovarian cancer
por: Ahn, Ji-Hye, et al.
Publicado: (2018)

“Real life” use of raltegravir during pregnancy in France: The Coferal-IMEA048 cohort study
por: Gantner, Pierre, et al.
Publicado: (2019)

Safety analysis of raltegravir/truvada regimen in HIV/HCV co-infected patients without switchback after HCV treatment
por: Ehret, Robert, et al.
Publicado: (2014)

Raltegravir: first in class HIV integrase inhibitor
por: Temesgen, Zelalem, et al.
Publicado: (2008)

Role of raltegravir in the management of HIV-1 infection
por: Okeke, N Lance, et al.
Publicado: (2011)

Raltegravir: molecular basis of its mechanism of action
por: Mouscadet, Jean-François, et al.
Publicado: (2009)

Switch to raltegravir-based regimens and HIV DNA decrease in patients with suppressed HIV RNA
por: Bianco, Claudia, et al.
Publicado: (2014)

Raltegravir-based Postnatal HIV Prophylaxis Therapy in a Neonate After in Utero Dolutegravir Exposure
por: Jacobs, Tom G., et al.
Publicado: (2022)

Incidence of cancer and overall risk of mortality in individuals treated with raltegravir‐based and non‐raltegravir‐based combination antiretroviral therapy regimens
por: Cozzi‐Lepri, A, et al.
Publicado: (2017)

A Novel Type of Non-coding RNA, nc886, Implicated in Tumor Sensing and Suppression
por: Lee, Yong Sun
Publicado: (2015)

Mechanism mediated by a noncoding RNA, nc886, in the cytotoxicity of a DNA-reactive compound
por: Kunkeaw, Nawapol, et al.
Publicado: (2019)

Nc886, a Novel Suppressor of the Type I Interferon Response Upon Pathogen Intrusion
por: Lee, Yeon-Su, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_67qk4e4oksemnptasu5mn60d08